LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

Search

Cogent Biosciences Inc

Ouvert

38.61 5.03

Résumé

Variation du prix de l'action

24h

Actuel

Min

36.94

Max

38.98

Chiffres clés

By Trading Economics

Revenu

-7.4M

-81M

BPA

-0.5

Employés

205

EBITDA

-6.8M

-79M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+39.74% upside

Dividendes

By Dow Jones

Prochains Résultats

5 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

3.4B

5.6B

Ouverture précédente

33.58

Clôture précédente

38.61

Score Technique

By Trading Central

Confiance

Bearish Evidence

Cogent Biosciences Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 févr. 2026, 22:53 UTC

Acquisitions, Fusions, Rachats

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 févr. 2026, 22:36 UTC

Résultats

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 févr. 2026, 22:32 UTC

Résultats

Woodside Energy Fiscal Year Net Profit Falls 24%

23 févr. 2026, 23:58 UTC

Market Talk
Résultats

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 févr. 2026, 23:58 UTC

Market Talk
Résultats

Global Energy Roundup: Market Talk

23 févr. 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 févr. 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 févr. 2026, 23:41 UTC

Acquisitions, Fusions, Rachats

Crescent Capital Partners Owns 53% of ClearView Wealth

23 févr. 2026, 23:40 UTC

Acquisitions, Fusions, Rachats

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 févr. 2026, 23:40 UTC

Acquisitions, Fusions, Rachats

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 févr. 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 févr. 2026, 23:40 UTC

Acquisitions, Fusions, Rachats

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 févr. 2026, 23:39 UTC

Acquisitions, Fusions, Rachats

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 févr. 2026, 23:31 UTC

Résultats

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 févr. 2026, 23:31 UTC

Résultats

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 févr. 2026, 23:28 UTC

Résultats

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 févr. 2026, 23:28 UTC

Résultats

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 févr. 2026, 23:28 UTC

Résultats

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 févr. 2026, 23:27 UTC

Résultats

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 févr. 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 févr. 2026, 22:38 UTC

Acquisitions, Fusions, Rachats

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 févr. 2026, 22:31 UTC

Résultats

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 févr. 2026, 22:24 UTC

Résultats

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 févr. 2026, 22:22 UTC

Résultats

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 févr. 2026, 22:22 UTC

Résultats

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 févr. 2026, 22:22 UTC

Résultats

Viva Energy FY Underlying Ebitda A$700.9 Million

23 févr. 2026, 22:22 UTC

Résultats

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 févr. 2026, 22:21 UTC

Résultats

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 févr. 2026, 22:21 UTC

Résultats

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 févr. 2026, 22:20 UTC

Résultats

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Comparaison

Variation de prix

Cogent Biosciences Inc prévision

Objectif de Prix

By TipRanks

39.74% hausse

Prévisions sur 12 Mois

Moyen 52.18 USD  39.74%

Haut 67 USD

Bas 35 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

10

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

4.88 / 5.87Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Strong Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
help-icon Live chat